ES2188929T3 - Analogos 2-peptidicos de tipo glucagon. - Google Patents

Analogos 2-peptidicos de tipo glucagon.

Info

Publication number
ES2188929T3
ES2188929T3 ES97916280T ES97916280T ES2188929T3 ES 2188929 T3 ES2188929 T3 ES 2188929T3 ES 97916280 T ES97916280 T ES 97916280T ES 97916280 T ES97916280 T ES 97916280T ES 2188929 T3 ES2188929 T3 ES 2188929T3
Authority
ES
Spain
Prior art keywords
glucagon
analogs
glucagon type
peptidal
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916280T
Other languages
English (en)
Inventor
Daniel J Drucker
Anna E Crivici
Martin Sumner-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1149336 Ontario Inc
NPS Allelix Corp Canada
Original Assignee
1149336 Ontario Inc
NPS Allelix Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2188929(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 1149336 Ontario Inc, NPS Allelix Corp Canada filed Critical 1149336 Ontario Inc
Application granted granted Critical
Publication of ES2188929T3 publication Critical patent/ES2188929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

ANALOGOS DEL PEPTIDO - 2 TIPO GLUCAGON, UN PRODUCTO DE EXPRESION GENICA DE GLUCAGON, SE HAN IDENTIFICADO COMO FACTORES DE CRECIMIENTO DEL TEJIDO INTESTINAL. SE DESCRIBE SU FORMULACION PARA SU USO FARMACEUTICO Y TERAPEUTICO EN EL TRATAMIENTO DE TRASTORNOS DEL INTESTINO DELGADO.
ES97916280T 1996-04-12 1997-04-11 Analogos 2-peptidicos de tipo glucagon. Expired - Lifetime ES2188929T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12

Publications (1)

Publication Number Publication Date
ES2188929T3 true ES2188929T3 (es) 2003-07-01

Family

ID=24530501

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97916280T Expired - Lifetime ES2188929T3 (es) 1996-04-12 1997-04-11 Analogos 2-peptidicos de tipo glucagon.
ES01129072T Expired - Lifetime ES2351661T3 (es) 1996-04-12 1997-04-11 Péptido-2 análogo al glucagón.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01129072T Expired - Lifetime ES2351661T3 (es) 1996-04-12 1997-04-11 Péptido-2 análogo al glucagón.

Country Status (16)

Country Link
EP (5) EP2275438A1 (es)
JP (3) JP4148994B2 (es)
CN (1) CN1268640C (es)
AT (2) ATE227309T1 (es)
AU (1) AU733857B2 (es)
BR (1) BRPI9708566B8 (es)
CA (1) CA2251576C (es)
DE (2) DE69716905T2 (es)
DK (2) DK0906338T3 (es)
ES (2) ES2188929T3 (es)
FR (1) FR13C0013I2 (es)
HK (1) HK1050204B (es)
LU (1) LU92153I2 (es)
NZ (1) NZ332281A (es)
PT (2) PT906338E (es)
WO (1) WO1997039031A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP2275438A1 (en) 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ATE253375T1 (de) * 1997-05-16 2003-11-15 Ontario Inc 1149336 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
AU2712899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
PT1326630E (pt) 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
DE602004022177D1 (de) * 2003-08-21 2009-09-03 Novo Nordisk As Reinigung glucagonähnlicher peptide
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
DK1809318T3 (da) 2004-11-01 2013-09-08 Nps Pharma Inc Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
CA2778890A1 (en) * 2009-10-30 2011-05-05 Otsuka Chemical Co., Ltd. Glycosylated form of antigenic glp-1 analogue
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2569001A4 (en) * 2010-05-11 2014-06-25 Nps Pharma Inc PROCEDURE FOR TREATING OR PREVENTING KIDNEY OR REFUSE FUNCTIONS
US20140249090A1 (en) 2011-04-01 2014-09-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaft e.V. Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US10774127B2 (en) * 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
US20250304643A1 (en) * 2021-12-17 2025-10-02 Bainan Biotech Aps Peptide dual agonists of gipr and glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1975177B1 (en) 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
EP2275438A1 (en) 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
DK0906338T3 (da) 2003-03-03
AU2500297A (en) 1997-11-07
FR13C0013I2 (fr) 2013-08-16
HK1147761A1 (en) 2011-08-19
CA2251576C (en) 2012-08-21
LU92153I2 (fr) 2013-04-19
EP1231219A1 (en) 2002-08-14
CN1244872A (zh) 2000-02-16
EP2218734A2 (en) 2010-08-18
AU733857B2 (en) 2001-05-31
FR13C0013I1 (es) 2013-05-04
DE60142885D1 (de) 2010-10-07
ATE227309T1 (de) 2002-11-15
HK1050204A1 (en) 2003-06-13
DK1231219T3 (da) 2010-12-20
DE69716905T2 (de) 2003-07-24
BRPI9708566B8 (pt) 2022-01-18
ES2351661T3 (es) 2011-02-09
PT906338E (pt) 2003-03-31
JP2008184465A (ja) 2008-08-14
NZ332281A (en) 2000-03-27
EP0906338A1 (en) 1999-04-07
JP2007204491A (ja) 2007-08-16
EP2218734A3 (en) 2010-10-13
EP2275438A1 (en) 2011-01-19
JP2000511881A (ja) 2000-09-12
WO1997039031A1 (en) 1997-10-23
PT1231219E (pt) 2010-11-30
BR9708566B1 (pt) 2012-09-04
EP2218734B1 (en) 2013-06-05
ATE478892T1 (de) 2010-09-15
JP4148994B2 (ja) 2008-09-10
JP5019466B2 (ja) 2012-09-05
EP0906338B1 (en) 2002-11-06
BRPI9708566A (pt) 2000-01-04
EP1231219B1 (en) 2010-08-25
JP4149497B2 (ja) 2008-09-10
DE69716905D1 (de) 2002-12-12
HK1033324A1 (en) 2001-08-24
EP2009024A1 (en) 2008-12-31
CA2251576A1 (en) 1997-10-23
HK1050204B (en) 2011-09-23
CN1268640C (zh) 2006-08-09

Similar Documents

Publication Publication Date Title
BRPI9708566A (pt) Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.
PT830377E (pt) Péptido-2 análogo ao glucagon e sua utilização terapêutica
AR013612A1 (es) Colostrinina y usos de la misma para la manufactura de un medicamento, una composicion farmaceutica que la comprende, uso de la misma como suplemento dedieta, un suplemento de dieta, un nonapeptido, el uso del mismo para la manufactura de un medicamento, composicion farmaceutica y metodo para prepar
ES2191192T3 (es) Tienopirimidinas.
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
ES2132105T3 (es) 2-aminometil-cromanos como principios activos en farmacos para el tratamiento de enfermedades del sistema nervioso central.
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
PT703786E (pt) Utilizacao de nonapeptideos e decapeptideos para a preparacao de um medicamento para o tratamento da sida
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
MY125978A (en) Admantane derivatives
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
IL112111A (en) Peptides having growth hormone releasing properties and pharmaceutical compositions containing them
ES2102010T3 (es) Composiciones farmaceuticas de bacteriocina y su utilizacion para el tratamiento de trastornos gastrointestinales.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
PA8504301A1 (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba
ES2185897T3 (es) Uso de 2-carnitinas de alcanoilo para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias del intestino.
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
DE3770766D1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
ES2196456T3 (es) Compuestos ciclicos de cinco eslabones en el anillo condensado que llevan un grupo sulfonamida, su uso como medicamentos y composiciones farmaceuticas que los contienen.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2175582T3 (es) Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su utilizacion como medicamento, asi como preparados farmaceuticos que los contienen.
ES2188140T3 (es) Utilizacion del factor de crecimiento de monocitos cd137 o un analogo funcional del mismo para producir un medicamento.
MX2023013301A (es) Una pluralidad de particulas tasquinimod y su uso.